Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sitravatinib - Mirati Therapeutics

Drug Profile

Sitravatinib - Mirati Therapeutics

Alternative Names: MG-516; MG91516; MGCD-0516; MGCD-516; Sitravatinib-malate; Sitravatinib-malate-Mirati-Therapeutics

Latest Information Update: 22 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MethylGene
  • Developer BeiGene; Bristol-Myers Squibb; Cancer Research UK; Columbia University; Mirati Therapeutics; University Health Network; University of Birmingham
  • Class Antineoplastics; Cyclopropanes; Pyridines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Eph family receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-mer inhibitors; Receptor protein-tyrosine kinase antagonists; RON protein inhibitors; TIE 2 receptor antagonists; Tropomyosin-related kinase antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Liposarcoma; Renal cell carcinoma; Soft tissue sarcoma; Urogenital cancer
  • Phase I/II Gastric cancer; Liver cancer
  • Phase I Cancer; Ovarian cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 23 Dec 2019 Phase-I clinical trials in Cancer (In volunteers) in Netherlands (PO)
  • 13 Dec 2019 Efficacy and adverse events data from a phase Ib trial in Solid tumours presented at the 44th European Society for Medical Oncology Congress (ESMO-2019)
  • 22 Nov 2019 Interim efficacy data from a phase I SNOW trial in Squamous cell cancer presented at the 34th Annual Meeting of The Society of Immunotherapy of Cancer (STIC-2019)[700297283]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top